Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

MBX Biosciences (MBX) EBITDA (2023 - 2026)

MBX Biosciences has reported EBITDA over the past 4 years, most recently at -$24.4 million for Q1 2026.

  • Quarterly results put EBITDA at -$24.4 million for Q1 2026, down 2.21% from a year ago — trailing twelve months through Mar 2026 was -$87.3 million (down 18.88% YoY), and the annual figure for FY2025 was -$86.7 million, down 40.07%.
  • EBITDA reached -$24.4 million in Q1 2026 per MBX's latest filing, down from -$21.9 million in the prior quarter.
  • Across five years, EBITDA topped out at -$8.8 million in Q4 2023 and bottomed at -$24.4 million in Q1 2026.
  • Median EBITDA over the past 4 years was -$18.0 million (2024), compared with a mean of -$17.5 million.
  • The largest annual shift saw EBITDA tumbled 92.6% in 2025 before it dropped 2.21% in 2026.
  • Over 4 years, EBITDA stood at -$8.8 million in 2023, then plummeted by 77.85% to -$15.6 million in 2024, then tumbled by 40.24% to -$21.9 million in 2025, then fell by 11.3% to -$24.4 million in 2026.
  • Business Quant data shows EBITDA for MBX at -$24.4 million in Q1 2026, -$21.9 million in Q4 2025, and -$21.5 million in Q3 2025.